Regeneron and Sanofi announce FDA approval of Dupixent

First targeted biologic therapy for adults with moderate-to-severe atopic dermatitis.

"People with moderate-to severe atopic dermatitis cope with intense, sometimes unbearable symptoms that can impact them for most of their lives," said Julie Block, President and CEO, National Eczema Association. "To date, there have been few options available to treat people with moderate-to-severe atopic dermatitis who have uncontrolled disease. That's why today's approval of Dupixent is so important for our community. Now we have a treatment that is expected to help address patients suffering from this devastating disease."

Dupixent is a human monoclonal antibody that is designed to specifically inhibit overactive signaling of two key proteins, IL-4 and IL-13, which are believed to be major drivers of the persistent underlying inflammation in AD. Dupixent comes in a pre-filled syringe and can be self-administered as a subcutaneous injection every other week after an initial loading dose. Dupixent can be used with or without topical corticosteroids. It should not be used in patients who are allergic to dupilumab or any of the ingredients in Dupixent.

"Dupixent is the result of years of tireless research by our scientists into the underlying causes of allergic and atopic diseases. In atopic dermatitis, Dupixent was shown to help clear the skin and manage the intense itch caused by the disease," said George D. Yancopoulos, Founding Scientist, President, and Chief Scientific Officer, Regeneron. "Today's approval would not be possible without the dedication of the clinical investigators and the participation of the patients who took part in the global LIBERTY AD clinical program."

Dupixent was evaluated by the FDA with Priority Review. This followed the FDA's 2014 Breakthrough Therapy designation for Dupixent for inadequately controlled moderate-to-severe AD. Breakthrough Therapy designation was created by the FDA to expedite the development and review of drugs developed for serious or life-threatening conditions. Dupixent represents the first time this designation was granted for a dermatological disease, other than in dermatologic cancers.

"We strive to transform scientific innovation into therapeutic solutions that make a meaningful difference to people's lives," said Olivier Brandicourt, CEO, Sanofi. "The approval of Dupixent offers new hope for adults with moderate-to-severe AD in the US, and we look forward to working with regulatory authorities around the world to bring this important new medicine to patients globally."

Regeneron and Sanofi Genzyme, the specialty care global business unit of Sanofi, will market Dupixent in the US. Dupixent is expected to be available to patients and providers in the US later this week.